Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Some are verifiable through a Press & Media section, which is better than most clinics manage
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
Studies included in all three reviews were conducted mainly in middle- and high-income countries, with limited or no representation from regions such as Africa, Central America, and Southeast Asia
VTX3232 (Zomagen Biosciences) is currently being studied in a Phase 2a study
This is readily available and easy to administer
US$ 23.37
US$ 23.50
US$ 27.72
US$ 20.80
US$ 20.26
US$ 29.20
